EP Patent

EP3661935B1 — Substituted pyrazolopyrimidines useful as kinases inhibitors

Assigned to TELIGENE Ltd · Expires 2022-10-12 · 4y expired

What this patent protects

Patent listed against larotrectinib-sulfate.

Drugs covered by this patent

larotrectinib-sulfate (LAROTRECTINIB SULFATE)

Patent Metadata

Patent number: EP3661935B1
Jurisdiction: EP
Classification: —
Expires: 2022-10-12
Drug substance claim: No
Drug product claim: No
Assignee: TELIGENE Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.